Advertisement

SAN DIEGO (AP) — Development-stage biotechnology company Arena Pharmaceuticals Inc. said it started an early-stage study of a potential narcolepsy and cataplexy treatment.

Narcolepsy is a sleep disorder and cataplexy is a sudden loss of muscle tone that frequently affects people with narcolepsy.

The early-stage, or Phase 1 clinical trial on APD916 will involve up to 72 healthy adults and test mainly for safety and tolerability.

 

Advertisement
Advertisement